|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 24, 2016 ) As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.
The HIV therapeutics market in China was valued at approximately $144m in 2013. In contrast to the 7MM, where branded therapies dominate the treatment landscape, generics are beginning to seize market share from their pricier alternatives, and they will continue to gain traction during the forecast period, as China is expected to adopt a more aggressive policy towards identifying and treating people living with HIV.
Scope
- Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the China including product description, safety and efficacy profiles as well as a SWOT analysis.
Browse full report with TOC at : https://marketreportscenter.com/reports/387687/human-immunodeficiency-virus-hiv-china-drug-forecast-and-market-analysis-to-2023
- Sales forecast for the top drugs in the China from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the China Human Immunodeficiency Virus (HIV) market.
Receive copy of sample report at : https://marketreportscenter.com/request-sample/387687
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV).
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the China.
Receive Discount at : https://marketreportscenter.com/request-discount/387687
Media contacts:
Sam Collins
Market Reports Center
Call : 1-646-883-3044 (US)
Email : info@marketreportscenter.com
visit our website : https://marketreportscenter.com
Market Reports Center
Sam Collins
1-646-883-3044
sam@marketreportscenter.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
